Qlaris Bio is a clinical-stage biotechnology company with a visionary approach to preserving vision and preventing blindness. Their relentless commitment is evident in their pursuit of developing innovative first-in-class therapies for patients suffering from serious and debilitating ophthalmic diseases. Qlaris Bio explores novel mechanisms of action to address the largest unmet needs in ophthalmology.

Their lead asset, QLS-111, has a unique vasodilatory mechanism of action designed to lower intraocular pressure (IOP) by reducing episcleral venous pressure (EVP) and distal outflow resistance. This innovative treatment approach has the potential to achieve lower IOP targets not currently attainable with existing therapies. QLS-111 is currently in development for Normal Tension Glaucoma, Primary Open-Angle Glaucoma, Ocular Hypertension, and elevated IOP associated with rare diseases like Sturge-Weber Syndrome.

Qlaris Bio's dedication to advancing ophthalmic research and development has earned them recognition as a finalist for Biotech Company of the Year at the 2022 Scrip Awards. Their commitment to improving patients' lives is truly commendable. As they continue to push the boundaries of ophthalmic medicine, Qlaris Bio remains at the forefront of groundbreaking therapies for sight-threatening conditions